Novartis News | finanzen.ch

Novartis Aktie VALOR 1200526 / ISIN CH0012005267

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Trading-Depot

Aktion

Portfolio

Watchlist

27.03.18	Novartis to sell stake in consumer healthcare joint venture to GSK for USD13.0 billion to focus on strategic priorities (GlobeNewswire)
27.03.18	Novartis verkauft Beteiligung an Consumer-Healthcare-Joint-Venture für USD 13 Milliarden an GSK, um sich auf strategische Prioritäten zu konzentrieren (GlobeNewswire)
23.03.18	Sandoz receives positive CHMP opinion for proposed biosimilar infliximab (GlobeNewswire)
23.03.18	Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS (GlobeNewswire)
22.03.18	Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia (GlobeNewswire)
20.03.18	Novartis teams up with Harvard to develop next generation biomaterial systems to deliver immunotherapies (GlobeNewswire)
12.03.18	Novartis kündigt Veränderungen in der Geschäftsleitung zur Unterstützung strategischer Prioritäten an (GlobeNewswire)
12.03.18	Novartis announces changes to the Executive Committee to support strategic priorities (GlobeNewswire)
07.03.18	Novartis expands alliance with Science 37 to advance virtual clinical trials program (GlobeNewswire)
06.03.18	Novartis' Xolair® recommended in new global chronic urticaria guideline (GlobeNewswire)
02.03.18	Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting (GlobeNewswire)
02.03.18	Novartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats (GlobeNewswire)
01.03.18	Novartis and Pear Therapeutics to develop digital therapeutics for patients with schizophrenia and multiple sclerosis (GlobeNewswire)
22.02.18	Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation (GlobeNewswire)
16.02.18	Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis (GlobeNewswire)
16.02.18	Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis (GlobeNewswire)
14.02.18	Novartis forms alliance to develop medicines for treating infectious diarrheal disease (GlobeNewswire)
13.02.18	Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis (GlobeNewswire)
08.02.18	Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis (GlobeNewswire)
01.02.18	Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A. (GlobeNewswire)
31.01.18	Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL (GlobeNewswire)
26.01.18	Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors (GlobeNewswire)
24.01.18	Novartis exclusively licenses first ophthalmology gene therapy in all markets outside the US, a milestone for patients with rare inherited vision loss (GlobeNewswire)
24.01.18	Novartis erzielt 2017 eine gute operative Performance sowie wegweisende Innovationen und ist gut gerüstet für die nächste Wachstumsphase (GlobeNewswire)
24.01.18	Novartis delivered good operational performance and landmark innovation in 2017, entering our next growth phase (GlobeNewswire)
22.01.18	Novartis reports erenumab met all primary and secondary endpoints in unique Phase IIIb study in episodic migraine patients who have failed multiple prior preventive treatments (GlobeNewswire)
22.01.18	Novartis completes tender offer for Advanced Accelerator Applications S.A. and announces commencement of subsequent offering period (GlobeNewswire)
18.01.18	Sandoz announces exclusive global collaboration with Biocon on next-generation biosimilars (GlobeNewswire)
17.01.18	Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL (GlobeNewswire)
16.01.18	Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients (GlobeNewswire)
16.01.18	Sandoz regulatory submission for proposed biosimilar adalimumab accepted by FDA (GlobeNewswire)
11.01.18	Novartis ernennt Elizabeth Barrett zur Chefin Onkologie (GlobeNewswire)
11.01.18	Novartis appoints Elizabeth Barrett as Oncology Head (GlobeNewswire)
09.01.18	Novartis advances head-to-head superiority trials of Cosentyx® versus Humira®* and proposed biosimilar adalimumab** (GlobeNewswire)
04.01.18	Novartis drug Promacta® receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA) (GlobeNewswire)
03.01.18	Novartis Kisqali® received FDA Breakthrough Therapy designation for initial endocrine-based treatment in premenopausal women with HR+/HER2- advanced breast cancer (GlobeNewswire)
22.12.17	Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label (GlobeNewswire)
22.12.17	Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma (GlobeNewswire)
15.12.17	Novartis gibt Rücktritt des Onkologie-Chefs bekannt (GlobeNewswire)
15.12.17	Novartis announces Oncology head to retire (GlobeNewswire)
11.12.17	Novartis drug crizanlizumab shown to prolong time to patients' first sickle cell pain crisis in subgroup analysis of SUSTAIN study (GlobeNewswire)
10.12.17	Primary analysis results from Novartis pivotal JULIET trial show Kymriah(TM) (tisagenlecleucel) sustained complete responses at six months in adults with r/r DLBCL, a difficult-to-treat cancer (GlobeNewswire)
08.12.17	Sandoz announces new Phase I data showing proposed biosimilar pegfilgrastim matches reference medicine (GlobeNewswire)
07.12.17	Novartis tender offer for Advanced Accelerator Applications commences (GlobeNewswire)
06.12.17	Novartis Kisqali® is first and only CDK4/6 inhibitor to show superior median PFS compared to oral endocrine therapy as first-line treatment in a prospective, randomized Phase III trial dedicated to... (GlobeNewswire)
30.11.17	Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients (GlobeNewswire)
29.11.17	Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention (GlobeNewswire)
27.11.17	Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide® (GlobeNewswire)
20.11.17	Novartis drug Tasigna® (nilotinib) secures EU approval for first and second-line treatment of Ph+ CML-CP in children (GlobeNewswire)
15.11.17	Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania (GlobeNewswire)

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	262.10	3.39 %	K V
Lonza Grp	584.80	2.38 %	K V
Logitech Intl	66.76	1.71 %	K V
Part Grp Hldg	1’114.00	1.41 %	K V
Swisscom	544.00	0.74 %	K V
ABB	45.07	0.04 %	K V
Novartis	90.91	-0.22 %	K V
Zurich Insur Gr	581.00	-0.34 %	K V
Roche Hldg G	257.60	-0.88 %	K V
Kuehne+Nagel Int	177.85	-3.24 %	K V

mehr

10.05.25		April 2025: Analysten sehen weniger Potenzial bei Roche-Aktie
09.05.25		Novartis-Aktie: Das sind die Expertenmeinungen des Monats April
09.05.25		DAX 40-Wert Bayer-Aktie: So viel Verlust hätte ein Bayer-Investment von vor einem Jahr eingebracht
09.05.25		SMI-Papier Roche-Aktie: So viel Verlust hätte eine Investition in Roche von vor 10 Jahren bedeutet
08.05.25		NASDAQ Composite Index-Titel Gilead Sciences-Aktie: Über diese Dividendenzahlung können sich Gilead Sciences-Aktionäre freuen
08.05.25		Stoxx Europe 50-Papier GSK-Aktie: Über diese Dividendenzahlung können sich GSK-Anleger freuen
07.05.25		Aktien von Lonza, Roche, Novartis und Co. unter Druck: Weitere Belastungsfaktoren aus den USA